Paolo A. Ascierto, MD | Authors

October 17, 2018

Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.

July 18, 2018

Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.

September 13, 2017

Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab in patients with immunotherapy-relapsed/refractory melanoma.